



ASX Release

13/11/2020

RESULTS OF ANNUAL GENERAL MEETING

Perth, Australia; 13 November 2020: Emyria Limited (ASX:EMD, “Emyria” or the “Company”) advises that its 2020 Annual General Meeting was held today, 13 November 2020. All resolutions put to the meeting were passed on a Poll. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the Company advises that details of the poll results and the proxies received in respect of each resolution are set out below:

Poll Results

Resolutions		For	Against	Abstain
1	Adoption of Remuneration Report	33,800,011	0	39,297,619
2	Re-election of Professor Sir John Tooke	102,048,229	0	0
3	Approval of 10% Placement Facility	101,994,905	53,324	0
4	Ratification of prior issue of Placement Shares	101,927,286	153,324	97,619
5 (a)	Issue of Options to Dr Michael Winlo	33,445,437	188,324	39,463,869
5 (b)	Issue of Options to Dr Alistair Vickery	33,445,437	188,324	39,463,869
5 (c)	Issue of Options to Mr Matt Callahan	33,445,437	188,324	39,463,869
5 (d)	Issue of Options to Professor Sir John Tooke	33,445,437	188,324	39,463,869

Proxy Votes Received

Resolutions		For	Against	At Proxy Holders Discretion	Abstain
1	Adoption of Remuneration Report	28,355,479	0	14,000	39,297,619
2	Re-election of Professor Sir John Tooke	96,053,098	0	14,000	0
3	Approval of 10% Placement Facility	95,999,774	53,324	14,000	0
4	Ratification of prior issue of Placement Shares	95,792,155	153,324	24,000	97,619
5 (a)	Issue of Options to Dr Michael Winlo	28,000,905	188,324	14,000	39,463,869
5 (b)	Issue of Options to Dr Alistair Vickery	28,000,905	188,324	14,000	39,463,869
5 (c)	Issue of Options to Mr Matt Callahan	28,000,905	188,324	14,000	39,463,869
5 (d)	Issue of Options to Professor Sir John Tooke	28,000,905	188,324	14,000	39,463,869

Release authorised by:

Simon Robertson
Company Secretary



For further information

Dr Michael Winlo
CEO
(08) 6559 2800
mwinlo@emyria.com

Lexi O'Halloran
Media/Investor Relations
+ 61 (0) 404 577 076
lexi@janemorganmanagement.com.au

About Emyria (www.emyria.com)

Emyria Limited creates unique data products that accelerate the development of new treatments for patients with unmet needs. Emyria achieves this by analysing the deep, deidentified clinical data gathered from its specialist clinical network – **Emerald Clinics** (www.emeraldclinics.com.au) – and turning that into Real-World Evidence (RWE). Emyria's data products accelerate the development and registration of new and promising treatments for patients with unmet medical needs by providing unique, real-world insights into the safety, quality and efficacy of those unapproved treatments, in real patients in the community. Emyria's data assets are also a source of unique IP for Emyria, which along with its remote patient monitoring technologies, data platforms and care models, further improve the quality of its RWE data assets and insights as well as the care provided to patients.